DT204 is a SCFSkp2 inhibitor which blocks Skp2 binding to Cullin-1 and Commd1, thereby synergistically enhancing BTZ-induced apoptosis and stabilization. DT204 also increases p27 levels. References: Malek E, Abdel-Malek MA, Jagannathan S, Vad N, Karns R, Jegga AG, Broyl A, van Duin M, Sonneveld P, Cottini F, Anderson KC, Driscoll JJ. Pharmacogenomics and chemical library screens reveal a novel SCF(SKP2) inhibitor that overcomes Bortezomib resistance in multiple myeloma. Leukemia. 2017 Mar;31(3):645-653. doi: 10.1038/leu.2016.258. Epub 2016 Sep 28. PubMed PMID: 27677741; PubMed Central PMCID: PMC5339431.

纯度：≥98%

CAS：428497-71-6